Cargando…

Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance

Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardonova, Miroslava, Siarnik, Pavel, Sivakova, Monika, Sucha, Bianka, Penesova, Adela, Radikova, Zofia, Havranova, Andrea, Imrich, Richard, Vlcek, Miroslav, Zitnanova, Ingrid, Krastev, Georgi, Kiacikova, Maria, Kollar, Branislav, Turcani, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342844/
https://www.ncbi.nlm.nih.gov/pubmed/37446338
http://dx.doi.org/10.3390/ijms241311162
_version_ 1785072596526563328
author Hardonova, Miroslava
Siarnik, Pavel
Sivakova, Monika
Sucha, Bianka
Penesova, Adela
Radikova, Zofia
Havranova, Andrea
Imrich, Richard
Vlcek, Miroslav
Zitnanova, Ingrid
Krastev, Georgi
Kiacikova, Maria
Kollar, Branislav
Turcani, Peter
author_facet Hardonova, Miroslava
Siarnik, Pavel
Sivakova, Monika
Sucha, Bianka
Penesova, Adela
Radikova, Zofia
Havranova, Andrea
Imrich, Richard
Vlcek, Miroslav
Zitnanova, Ingrid
Krastev, Georgi
Kiacikova, Maria
Kollar, Branislav
Turcani, Peter
author_sort Hardonova, Miroslava
collection PubMed
description Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objective was to explore the changes in the endothelial function of MS patients after 12 months of GLP-1a therapy. We also explored the role of lipoprotein subfractions and the antioxidant capacity of plasma. Methods: MS patients were enrolled in a prospective, unicentric study. GLP-1a (dulaglutide) was administered to 13 patients. The control population consisted of 12 subjects. Endothelial function was determined by peripheral arterial tonometry and expressed as reperfusion hyperemia index (RHI). Trolox equivalent antioxidant capacity (TEAC) was used to assess the total antioxidant capacity of the plasma. The levels of lipoprotein subfractions were evaluated. Results: The GLP-1a group did not have a significant change in their RHIs after 12 months (2.1 ± 0.6 vs. 2.1 ± 0.7; p = 0.807). However, a significant increase in their TEACs was observed (4.1 ± 1.4 vs. 5.2 ± 0.5 mmol/L, p = 0.010). On the contrary, the subjects in the control group had a significant worsening of their RHIs (2.1 ± 0.5 vs. 1.8 ± 0.6; p = 0.030), without significant changes in their TEACs. Except for a significant decrease in very-low-density lipoprotein (VLDL) (30.8 ± 10.2 vs. 22.6 ± 8.3 mg/dL, p = 0.043), no other significant changes in the variables were observed in the control group. VLDL levels (beta = −0.637, p = 0.001), the use of GLP-1a therapy (beta = 0.560, p = 0.003), and small LDL (beta = 0.339, p = 0.043) were the only significant variables in the model that predicted the follow-up RHI. Conclusion: Our results suggest that the application of additional GLP-1a therapy may have atheroprotective and antioxidant effects in MS patients with high MS activity and thus may prospectively mitigate their vascular risk. However, the lipoprotein profile may also play an important role in the atherogenic risk of MS subjects.
format Online
Article
Text
id pubmed-10342844
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103428442023-07-14 Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance Hardonova, Miroslava Siarnik, Pavel Sivakova, Monika Sucha, Bianka Penesova, Adela Radikova, Zofia Havranova, Andrea Imrich, Richard Vlcek, Miroslav Zitnanova, Ingrid Krastev, Georgi Kiacikova, Maria Kollar, Branislav Turcani, Peter Int J Mol Sci Communication Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objective was to explore the changes in the endothelial function of MS patients after 12 months of GLP-1a therapy. We also explored the role of lipoprotein subfractions and the antioxidant capacity of plasma. Methods: MS patients were enrolled in a prospective, unicentric study. GLP-1a (dulaglutide) was administered to 13 patients. The control population consisted of 12 subjects. Endothelial function was determined by peripheral arterial tonometry and expressed as reperfusion hyperemia index (RHI). Trolox equivalent antioxidant capacity (TEAC) was used to assess the total antioxidant capacity of the plasma. The levels of lipoprotein subfractions were evaluated. Results: The GLP-1a group did not have a significant change in their RHIs after 12 months (2.1 ± 0.6 vs. 2.1 ± 0.7; p = 0.807). However, a significant increase in their TEACs was observed (4.1 ± 1.4 vs. 5.2 ± 0.5 mmol/L, p = 0.010). On the contrary, the subjects in the control group had a significant worsening of their RHIs (2.1 ± 0.5 vs. 1.8 ± 0.6; p = 0.030), without significant changes in their TEACs. Except for a significant decrease in very-low-density lipoprotein (VLDL) (30.8 ± 10.2 vs. 22.6 ± 8.3 mg/dL, p = 0.043), no other significant changes in the variables were observed in the control group. VLDL levels (beta = −0.637, p = 0.001), the use of GLP-1a therapy (beta = 0.560, p = 0.003), and small LDL (beta = 0.339, p = 0.043) were the only significant variables in the model that predicted the follow-up RHI. Conclusion: Our results suggest that the application of additional GLP-1a therapy may have atheroprotective and antioxidant effects in MS patients with high MS activity and thus may prospectively mitigate their vascular risk. However, the lipoprotein profile may also play an important role in the atherogenic risk of MS subjects. MDPI 2023-07-06 /pmc/articles/PMC10342844/ /pubmed/37446338 http://dx.doi.org/10.3390/ijms241311162 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Hardonova, Miroslava
Siarnik, Pavel
Sivakova, Monika
Sucha, Bianka
Penesova, Adela
Radikova, Zofia
Havranova, Andrea
Imrich, Richard
Vlcek, Miroslav
Zitnanova, Ingrid
Krastev, Georgi
Kiacikova, Maria
Kollar, Branislav
Turcani, Peter
Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title_full Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title_fullStr Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title_full_unstemmed Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title_short Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
title_sort endothelial function in patients with multiple sclerosis: the role of glp-1 agonists, lipoprotein subfractions, and redox balance
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342844/
https://www.ncbi.nlm.nih.gov/pubmed/37446338
http://dx.doi.org/10.3390/ijms241311162
work_keys_str_mv AT hardonovamiroslava endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT siarnikpavel endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT sivakovamonika endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT suchabianka endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT penesovaadela endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT radikovazofia endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT havranovaandrea endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT imrichrichard endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT vlcekmiroslav endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT zitnanovaingrid endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT krastevgeorgi endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT kiacikovamaria endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT kollarbranislav endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance
AT turcanipeter endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance